Author:
Boeck S.,Weigang-Köhler K.,Fuchs M.,Kettner E.,Quietzsch D.,Trojan J.,Stötzer O.,Zeuzem S.,Lordick F.,Köhne C-H.,Kröning H.,Steinmetz T.,Depenbrock H.,Heinemann V.
Reference27 articles.
1. Clinical cancer advanced 2005: major research advanced in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology;Herbst;J Clin Oncol,2006
2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997
3. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials;Heinemann;Semin Oncol,2002
4. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinicals trials group [NCIC-CTG];Moore;Proc Am Soc Clin Oncol,2005
5. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer;Cunningham;Eur J Cancer Suppl,2005
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献